JOINT FILING AGREEMENT
Exhibit 99.1
This Joint Filing Agreement, dated as of February 14, 2022, is by and between Cormorant Asset Management, LP and Xxxxx
Xxxx (collectively, the “Filers”).
Each of the Filers may be required to file with the United States Securities and Exchange Commission a statement on Schedule 13D and/or 13G
with respect to shares of Common Stock of Tango Therapeutics, Inc. beneficially owned by them from time to time.
Pursuant to and in accordance with Rule 13(d)(1)(k) promulgated under the Securities Exchange Act of 1934, as amended, the Filers hereby
agree to file a single statement on Schedule 13D and/or 13G (and any amendments thereto) on behalf of each of the Filers, and hereby further agree to file this Joint Filing Agreement as an exhibit to such statement, as required by such rule.
This Joint Filing Agreement may be terminated by any of the Filers upon written notice or such lesser period of notice as the Filers may
mutually agree.
Executed and delivered as of the date first above written.
By: Cormorant Asset Management GP, LLC
its General Partner
By: /s/ Xxxxx Xxxx
Xxxxx Xxxx, Managing Member
/s/ Xxxxx Xxxx
Xxxxx Xxxx